Search

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

Nov 28 2023 Posted in Meeting reports

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Publications

Cellular therapies in older adults with hematological malignancies: A case-based, state-of-the-art review
Neuendorff NR, Khan A, Ullrich F, Yates S, Devarakonda S, Lin RJ, von Tresckow B, Cordoba R, Artz A, Rosko AE. J Geriatr Oncol. 2024 Feb 29;15(3):101734.

Specialized Working Groups

EHA partners with Specialized Working Groups (SWGs) to foster science and to spread knowledge in basic, translational and clinical research in hematology in Europe.

Stem Cells

Mission:

The goal of the SWG on Stem Cells is to bring together researchers, biologists and clinicians involved in stem cell research to share their recent advances in the field, as well as to train new junior members.

SWG Educational Activities

EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).

Gaucher disease non-interventional clinical audit study

An activity of the GD Task Force, an independent sub-committee of the SWG on Granulocytes and Constitutional Marrow Failure Syndromes.

SWG Educational Activities

EHA2023 Hybrid CongressDate and locationJune 8–11, 2023, in Frankfurt, Germany. ChairMarie Jose Kersten

Case discussions
Follicular Lymphoma: Martin Dreylng, Daphne De Jong. Double hit Lymphoma: Andrew Davies, Elias Campo. T-follicular helper cell lymphoma: Andrew Davies, Daphne De Jong.

Executive office

The EHA Board and its committees are supported by the Executive Office. An international team of staff members work in a dynamic, result-driven and open environment and takes pride in serving the association in an efficient manner.

Publications

Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.